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Abstract
Background: Almost all of the extracellular matrix (ECM) components can be degraded by the endoproteinases matrix
metalloproteinases (MMPs). Important regulators of MMPs, and thereby of the extracellular environment, are tissue
inhibitors of metalloproteinases (TIMPs), and especially TIMP-1. Early tumor development, as well as distant metastasis,
may be results of an MMP/TIMP ratio imbalance altering the ECM. MMPs are elevated in several inflammatory conditions.
Our aim is to investigate the prognostic role of MMP-8, − 9, and TIMP-1 in colorectal cancer (CRC) and their relationship
to inflammation.
Methods: We included 337 colorectal cancer patients and 47 controls undergoing surgery at Helsinki University Hospital
in Finland, 1998–2011. Serum levels of MMP-8 and plasma levels of C-reactive protein (CRP) were determined with a time-
resolved immunofluorometric assay (IFMA), and MMP-9 and TIMP-1 with commercial enzyme-linked immunosorbent
assay (ELISA) kits. Association and correlation analyses were performed with the Mann-Whitney U, Kruskal-Wallis, and
Spearman rank correlation tests. Survival curves were constructed according to the Kaplan-Meier method and compared
with the log-rank test.
Results: Among patients with advanced disease, serum levels of MMP-8 and TIMP-1 were elevated. CRC
patients with high MMP-8 (HR (hazard ratio) 1.72, 95% confidence interval (CI) 1.17–2.52, P = 0.005) and those
with high TIMP-1 (HR 1.80, 95% CI 1.23–2.64, P = 0.002) had worse prognoses. MMP-9 level failed to serve as a
prognostic factor. In multivariable survival analysis, Dukes stage, and low MMP-9/TIMP-1 molar ratio (HR 0.46,
95% CI 0.33–0.98, P = 0.042) were independently predicted prognosis. A weak correlation between CRP and
MMP-8 (rS = 0.229, P < 0.001), and TIMP-1 (rS = 0.280, P < 0.001) was noted. Among patients showing no systemic
inflammatory response, MMP-8 (HR 1.66, 95% CI 1.10–2.53, P = 0.017) and TIMP-1 (HR 1.59, 95% CI 1.05–2.42, P = 0.029)
were prognostic factors.
Conclusions: MMP-8 and TIMP-1 in serum, but not MMP-9, identified CRC patients with bad prognosis. Among
patients showing no systemic inflammatory response, MMP-8 and TIMP-1 may associate with poor prognosis.
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Background
Colorectal cancer (CRC), one of the most common can-
cers, has a high morbidity level in developed countries [1,
2]. That survival has improved may be explained by
increased screening or early awareness, as well as by im-
proved treatment. Still, 17% of stage II and 36% of stage
III patients develop a recurrence within 5 years [3]. What
is of great importance is to recognize that these patients
need adjuvant treatment and intensive follow-up, whereas
others may be spared from laborious treatments.
Matrix metalloproteinases (MMPs) are a family of
structurally related zinc-dependent endopeptidases cap-
able of degrading almost all extraceullular matrix (ECM)
components [4]. Increased MMP activity is a result of
tumor cell-specific mechanisms such as angiogenesis
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and epithelial-mesenchymal transition (EMT). Addition-
ally, MMPs can process distinct non-matrix bioactive
substrates such as growth factors, complement compo-
nents, pro- and anti-inflammatory cytokines, chemokines,
serum proteins, and receptors. MMPs can thereby regu-
late immuneresponses [5, 6].
Of the 26 different MMPs recognized, several have
been studied extensively in inflammatory diseases and
cancer. MMP-8 and -9 belong to the collagenase sub-
group of MMPs being expressed – apart from tumor
cells – also by fibroblasts and infiltrating inflammatory
cells [7]. In benign tissues, the ECM environment is
strictly under the control, among others, of endogenous
proteins called tissue inhibitors of metalloproteinases
(TIMPs) [8]. TIMP-1 in particular serves by binding to
MMPs as an important regulator and may inhibit the
proteolytic activity of MMPs. Any imbalances in this
strictly controlled process may result in altered ECM
and early tumor development, and a disruption of the
MMP/TIMP ratio within the microenvironment may fa-
cilitate distant metastasis [9]. TIMP-1 also exerts
MMP-inhibition-independent characteristics such as
growth factor-like and proinflammatory properties [10].
Elevated levels of serum MMP-8, MMP-9, and TIMP-1
have appeared in several cancers: lung, gastric, hepatocellu-
lar, and colorectal, but also in melanoma and head and
neck cancer [11–17]. MMP-9 in particular has been exten-
sively studied for its effects on tumor cell invasion and
angiogenesis. The influence of elevated MMP-9 serum level
on prognosis and on its ability to serve as a diagnostic
maker have, however, varied [7]. MMP-8, on the other
hand, has not raised as much interest, although it regulates
many different proteins of the ECM [18]. High serum
MMP-8 level correlates with stage, but its effect on survival
was not reported there [14]. Some have shown that in colo-
rectal cancer, preoperative plasma TIMP-1 serves as an in-
dependent prognostic marker [19], whereas others found
only a limited value for TIMP-1 as a prognostic indicator
[20]. According to a meta-analysis based on five different
studies, colorectal cancer patients with elevated plasma or
serum TIMP-1 had poorer overall survival [21]. As the bal-
ance between MMPs and TIMP-1 is tightly regulated in
healthy tissues, their molar ratio may more specifically re-
flect the ECM environment in malignant lesions.
Colorectal cancer patients showing systemic inflamma-
tory response have a worse prognosis [22]. In multiple
other conditions linked to an activated inflammatory re-
sponse, such as acute coronary syndrome, chronic urti-
caria, or pancreatitis, correlations exist between high
MMP-9 levels and C-reactive protein (CRP) [23–25]. In
colorectal cancer, high serum MMP-8 levels and high
blood neutrophil and leukocyte count correlated posi-
tively [14], but correlations between TIMP-1 and white
blood cell count were less clear.
The aim of our study was to investigate the prognostic
roles of MMP-8, MMP-9, and TIMP-1 in colorectal can-
cer. Furthermore, we studied any possible relationship
between elevated MMP-levels and systemic inflamma-
tory response.
Methods
Patients
Of 384 patients undergoing surgery at Helsinki University
Hospital, Finland, 1998–2011, 335 underwent a primary
elective operation for colorectal cancer, and 47 with sur-
gery for other reasons served as benign controls. Colorec-
tal cancer (CRC) patients had surgery in 1998–2003 with
a median follow-up time of 6.4 years (range, 1 day to
16.3 years). At the end of follow-up, 200 (59.3%) had died.
The 5-year disease-specific survival for colorectal cancer
patients was 69.9% (95% confidence interval (CI) 64.6–
75.2), for colon cancer patients, it was 72.1% (95% CI
64.5–79.5), and for rectal cancer patients, 67.4% (95% CI
60.3–75.1). Of the CRC patients, 173 (51.3%) were men,
and 257 (76.3%) had surgery with curative intent. In 156
(46.6%) patients and the tumor was situated in the colon
and in 179 (53.4%) in the rectum; it was more frequently
located in the left side of the colorectum (242; 72.2%)
(Table 1).
Median age was for the 47 controls 54.0 (interquartile
range (IQR) 38.5–70.9), and 30 (64.8%) were women.
They underwent surgery for benign colorectal neoplasia
(18; 38.3%), inflammatory bowel disease (13; 27.7%), or
benign thyroid disease (11; 23.4%), and the other 5
(10.6%) for other reasons. Their 5-year overall survival
was 90.3% (95% CI 81.2–99.3).
Serum and plasma samples
Blood samples were obtained within 30 days prior to
surgery (range 0–30 days). The majority of the samples
(92.4%) were taken within 3 days preoperatively. The
samples were centrifuged, and serum and plasma com-
ponents stored as aliquots at − 80 °C until analysis. The
commercial MMP-9 and TIMP-1 enzyme-linked im-
munosorbent assay (ELISA) kits served for determin-
ation of serum levels in accordance with the
manufacturer’s instructions (Biotrak ELISA System;
Amersham Biosciences, Buckinghamshire, UK). For
MMP-9, the detection limit was 0.6 ng/ml and for
TIMP-1 1.25 ng/ml [6]. For MMP-8, we used the
time-resolved immunofluorometric assay (IFMA) (Medix
Biochemica, Espoo, Finland) in accordance with the
manufacturer’s instructions with a detection limit of
0.08 ng/ml [26].
We determined plasma CRP by a high-sensitivity
method; time-resolved IFMA, with a monoclonal CRP
antibody (anti-hCRP, code 6405, Medix Biochemica) as
previously described [27].
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Statistical analysis
To determine the significance of the difference in bio-
marker concentrations, the Mann-Whitney U-test and
Kruskal-Wallis test were applied. Correlations between
the biomarkers and CRP were explored by the Spearman
rank correlation test. We counted disease-specific sur-
vival from date of surgery to date of death from colorec-
tal cancer or until end of follow-up. We used the
Kaplan-Meier method to construct survival curves and
compared them with the log-rank test. For biomarkers
MMP-8, MMP-9, TIMP-1, MMP-8/TIMP-1, their molar
ratios, and the MMP-9/TIMP-1 molar ratio were
grouped as low or high according to their median values
for survival analyses. For CRP, a concentration of ≤30
mg/l served as the cut-off for dichotomization. The Cox
proportional hazard model served for multivariable sur-
vival analysis and we entered the following covariates:
gender, age, Dukes stage, grade, histologic type, tumor
location (colon vs. rectum), side (right vs. left), MMP-8,
− 9, TIMP-1, and CRP serum concentration, as well as
MMP/TIMP-1 molar ratios. Dukes’ classification and
grade, were entered as categorical covariates. Multivari-
able Cox regression analysis was performed according to
the backward stepwise method with removal of the term
at P < 0.1. Interaction terms were considered in the final
model, with no significant interactions found. The Cox
proportional hazard model assumption of constant haz-
ard ratios over time was tested by including a
time-dependent variable for each testable variable separ-
ately. All variables fulfilled the assumption. We consid-
ered P-values of < 0.05 statistically significant. We used
the IBM SPSS Statistics version 23.0 for Mac (IBM
Corporation, Armonk, NY, USA) for the statistical
analyses.
Results
Of median MMP-8, MMP-9, and TIMP-1 serum levels
prior to surgery for colorectal cancer and for controls
with benign disease, only TIMP-1 levels were higher in
patients with CRC than in controls (P = 0.037,
Mann-Whitney U-test, Table 2). No differences in molar
ratios of MMP/TIMP-1 were noted between cancer pa-
tients and controls. Colorectal cancer patients had
higher CRP levels than did controls (P < 0.001).
Association of MMP-8, MMP-9, and TIMP-1 with
clinicopathologic parameters
Serum levels of MMP-8 were higher among patients
with advanced disease, both in regard to locally ad-
vanced (pT4 tumors; P = 0.004) and distantly metasta-
sized disease (P < 0.001, Table 3). Serum MMP-8 was
also higher among those with the tumor located in the
right side of the colon (P = 0.038). Serum MMP-9 levels
were slightly higher in men (P = 0.015) and in those with
metastasized disease (P = 0.028). TIMP-1 serum levels
were likewise higher among patients with locally ad-
vanced disease (pT4 tumors; P = 0.028), as well as higher
among patients with a right-sided tumor (P = 0.016). In
Table 1 Characteristics of 335 colorectal cancer patients
Patient characteristics n (%)
Age
Median (IQR), years 67.2 (57.5–75.9)
Gender
Men 174 (51.9)
Women 161 (48.1)
Dukes classification
A 59 (17.6)
B 101 (30.1)
C 114 (34.0)
D 61 (18.2)
Tumor classification (pT)
pT1 13 (3.9)
pT2 74 (22.1)
pT3 212 (63.3)
pT4 31 (9.3)
Lymph node metastasis (pN)
pN0 176 (52.5)
pN1 87 (26.0)
pN2 68 (20.3)
Distant metastasis (pM)
pM0 273 (81.5)
pM1 58 (17.3)
Grade (WHO)
1 22 (6.6)
2 31 (69.0)
3 24 (7.2)
4 22 (6.6)
Location
Colon 156 (46.6)
Rectum 179 (53.4)
Side
Right 93 (27.8)
Left 242 (72.2)
Histologic type
Adeno 309 (92.2)
Mucinous 26 (7.8)
Systemic inflammatory response
CRP < =30 278 (83.0)
CRP > 30 51 (15.2)
Abbreviation: IQR interquartile range
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addition, serum TIMP-1 was higher among patients over
65 (P < 0.001).
The MMP-8/TIMP-1 molar ratio was as well higher
among patients with metastasized disease (P < 0.001,
Additional file 1). The MMP-9/TIMP-1 molar ratio was
higher among patients under 65 (P = 0.002).
We found weak positive correlations between MMP-8
and CRP (rS = 0.229, p < 0.001, Spearman rank correlation
test), between TIMP-1 and CRP (rS = 0.280, P < 0.001),
and between MMP-8/TIMP-1 molar ratio and CRP (rS =
0.151, P = 0.007). No significant correlation was noted be-
tween MMP-9 and CRP (rS = 0.110, P = 0.050) or MMP-9/
TIMP-1 molar ratio and CRP (rS = − 0.023, P = 0.678).
Univariable survival analyses
Five-year disease-specific survival according to dichoto-
mized MMP-8, − 9, and TIMP-1 concentrations and
MMP/TIMP-1 molar ratios are in Additional file 2 and
univariable hazard ratios in Table 4. Colorectal cancer pa-
tients with low MMP-8 levels had a 5-year survival of
76.0% (95% CI 69.1–82.9) and those with high MMP-8
levels 62.7% (95% CI 54.7–70.7; HR (hazard ratio) 1.72,
95% CI 1.17–2.52, P = 0.005; Fig. 1). Patients with low
TIMP-1 levels had a 5-year survival of 76.4% (95% CI
69.7–83.1) and those with high TIMP-1 levels 62.6% (95%
CI 54.6–70.6; HR 1.80, 95% CI 1.23–2.64, P = 0.002). Pa-
tients with high MMP-8/TIMP-1 molar ratio had better
survival (HR 1.48, 95% CI 1.0–2.16, P = 0.045), whereas
patients with a low MMP-9/TIMP-1 molar ratio survived
longer (HR 0.65, 95% CI 0.45–0.96, P = 0.027; Add-
itional file 2 and Table 4). MMP-9 level did not serve as a
prognostic factor.
In subgroup analyses, survival was poor for patients with
high MMP-8 and colon cancer (HR 2.00, 95% CI 1.10–3.64,
P = 0.023, Additional file 3), with left-sided tumor (HR 1.80,
95% CI 1.17–2.77, P = 0.007), and with no systemic inflam-
matory response (HR 1.66, 95% CI 1.10–2.53, P = 0.017,
Fig. 2a-b). Low levels of MMP-9 indicated poor prognosis
among rectal cancer patients (HR 0.49, 95% CI 0.28–0.85,
P = 0.011; Additional file 3). High TIMP-1 levels indicated
poor survival among patients with rectal cancer (HR 1.95,
95% CI 1.17–3.26, P = 0.011), with left-sided tumor (HR
1.95, 95% CI 1.27–3.00, P = 0.002), and with low CRP (HR
1.59, 95% CI 1.05–2.42, P = 0.029, Fig. 2c-d).
Multivariable survival analysis
We found that age, Dukes stage, and low MMP-9/
TIMP-1 molar ratio (HR 0.46, 95% CI 0.33–0.98, P =
0.042) served as independent prognostic factors
(Table 5).
Discussion
In colorectal cancer, we found that high levels of serum
MMP-8 and TIMP-1 serve as prognostic factors. Interest-
ingly, serum MMP-9 did not influence prognosis, but low
MMP-9/TIMP-1 molar ratio, together with high age and
advanced Dukes stage, were each independent prognostic
factors for poor prognosis. We noted that high MMP-8 and
TIMP-1 associated with advanced stage and right-sided lo-
cation. Among patients with normal CRP, indicating lack of
systemic inflammatory response, high MMP-8 and TIMP-1
selected patients with poor prognosis.
Few studies concern the prognostic value of MMP-8,
MMP-9, or TIMP-1 in colorectal cancer. In a study with
148 colorectal cancer patients, high serum MMP-8 and
TIMP-1 associated with advanced stage [14]. In another,
with 97 colon cancer patients, high TIMP-1 associated
with shorter overall survival and emerged as an independ-
ent prognostic factor [28]. We also found an association
between advanced stage (Dukes D) and high serum
MMP-8 and TIMP-1. Among patients with metastasized
disease, MMP-8 and TIMP-1 were more commonly ele-
vated; their levels were higher among those with
right-sided disease, which has not been previously re-
ported. We measured MMP-9 and TIMP-1 serum levels
by ELISA and MMP-8 with an IFMA method, in contrast
to that of with another group, which utilized
gelatin-zymography (SDS-PAGE) to detect MMP-9 levels
[15]. In their 32 colorectal cancer patients, MMP-2 and
MMP-9 seemed to correlate with more advanced stage;
Table 2 Median serum concentrations of MMP-8, MMP-9, TIMP-1, and molar ratios of MMPs and TIMP-1 in 335 colorectal cancer and 47
control patients
Colorectal cancer Controls
Median IQR Median IQR P-valuea
MMP-8 (ng/ml) 60 33–118 68 39–107 0.358
MMP-9 (ng/ml) 192 123–273 159 60–252 0.216
TIMP-1 (ng/ml) 151 131–180 139 125–161 0.037
MMP-8/TIMP-1 (molar ratio) 0.158 0.094–0.314 0.208 0.130–0.345 0.109
MMP-9/TIMP-1 (molar ratio) 0.368 0.216–0.539 0.343 0.139–0.610 0.755
CRP (mg/l) 4.85 1.92–15.6 1.21 0.404–4.14 < 0.001
Abbreviations: MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinases-1, CRP C-reactive protein, IQR interquartile range
aMann-Whitney U-test
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however, by this method, their results may be, at least in
part, uncertain [15]. Gelatin-zymography assaying semi-
quantitatively SDS-treated catalytic activities of MMP-2
and -9 does not analyze the concentrations of MMP-2
and -9 as precisely as do IFMA and ELISA utilizing highly
specific antibodies [29]. Their conclusion that MMP-9
would serve as an independent prognostic marker cannot
be drawn based on their results. All in all, MMP-8 and
TIMP-1 seem to influence the prognosis of colorectal can-
cer patients to a greater extent than MMP-9 seems to do.
Table 3 Significance of the difference in MMP-8, −9, and TIMP-1 serum concentrations in 330 colorectal cancer patients
Clinicopathological
variable
MMP-8 MMP-9 TIMP-1
Median (IQR) P-value Median (IQR) P-value Median (IQR) P-value
Agea
< =65 56 (36–97) 0.773 205 (136–287) 0.159 138 (123–162) < 0.001
> 65 63 (32–125) 185 (123–265) 164 (141–196)
Gendera
Male 60 (32–122) 0.861 209 (141–299) 0.015 154 (135–185) 0.020
Female 57 (35–112) 183 (105–254) 147 (123–177)
Dukes classificationb
A 50 (31–76) < 0.001 171 (95–269) 0.040 142 (122–163) 0.024
B 55 (33–90) 194 (131–318) 153 (131–183)
C 51 (30–101) 183 (123–246) 152 (134–178)
D 137 (56–328) 223 (161–310) 166 (132–257)
pTb
pT1 50 (22–64) 0.004 237 (83–297) 0.113 144 (117–190) 0.028
pT2 50 (27–90) 164 (101–244) 144 (126–166)
pT3 58 (34–129) 195 (128–287) 152 (131–179)
pT4 93 (58–265) 211 (165–284) 180 (148–244)
pNb
pN0 56 (33–93) 0.238 148 (127–175) 0.183 149 (127) 0.372
pN1 64 (33–93) 154 (135–181) 154 (135–181)
pN2 63 (35–140) 160 (130–188) 160 (130–188)
pMa
pM0 54 (32–94) < 0.001 189 (121–265) 0.028 150 (131–175) 0.054
pM1 118 (56–332) 221 (159–304) 165 (131–259)
Grade (WHO)b
1 66 (34–173) 0.227 204 (137–293) 0.717 166 (110–197) 0.727
2 60 (33–113) 193 (116–273) 150 (131–179)
3 41 (27–78) 159 (136–299) 163 (137–182)
4 102 (36–185) 215 (183–273) 157 (126–189)
Locationa
Colon 65 (35–134) 0.104 204 (143–284) 0.116 157 (131–187) 0.053
Rectum 54 (32–103) 185 (109–273) 148 (131–174)
Sidea
Right 70 (39–134) 0.038 208 (152–290) 0.266 161 (135 (191) 0.016
Left 54 (32–104) 189 (120–273) 149 (130–175)
Histologic typea
Adeno 58 (33–120) 0.726 192 (125–274) 0.374 152 (131–182) 0.558
Mucinous 63 (40–96) 221 (157–320) 156 (126–198)
Abbreviations: MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of matrix metalloproteinase-1, IQR interquartile range
aMann-Whitney U-test, bKruskal-Wallis test
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In hepatocellular carcinoma, high levels of MMP-8
and TIMP-1 have indicated poor survival, as did our
levels in CRC [13]. We found in CRC that although
MMP-9 levels had no influence on survival, patients
with a low MMP-9/TIMP-1 ratio had impaired survival,
in line with their results in hepatocellular carcinoma.
Similar findings have appeared also in patients with ma-
lignant melanoma, for whom high TIMP-1 indicated im-
paired disease-free survival [16], and in head and neck
squamous cell carcinoma patients who had shorter
disease-free survival [17].
Prognosis is worse for patients with right-sided colo-
rectal (RCC) than with left-sided colorectal cancer
(LCC) [30]. Right-sided tumors more frequently are
microsatellite instable and, express KRAS and BRAF mu-
tations, whereas LCC patients more frequently have mu-
tations in p53, NRAS, and show chromosomal instability
(CIN) which may imply a different genetic background
[31, 32]. Moreover, patients with RCC microsatellite
stable tumors have a significantly worse prognosis than
those that have microsatellite instable tumors [31]. Al-
though MMP-8 and TIMP-1 expression more frequently
was higher in patients with right-sided tumors, MMP-8
and TIMP-1 did not serve as prognostic factors among
these subgroups. On the contrary, we found that high
MMP-8 served as a prognostic factor in the subgroup of
colon cancer and patients with tumors located on the
left side of the colorectum.
Among colon cancer patients, especially within those
with left-sided disease, MMP-8 served as a prognostic
factor. In rectal cancer, high MMP-9 and high TIMP-1
served as prognostic factors. In addition, high TIMP-1
was an indicator of poor prognosis among patients with
Table 4 Univariable Cox regression analysis of disease-specific
survival for colorectal cancer patients
Hazard ratio 95% CI P-value
Age, years
< =65 1.00
> 65 1.44 0.98–2.10 0.062
Gender
Male 1.00
Female 1.06 0.73–1.54 0.772
Dukes classification
A 1.00
B 3.33 0.96–11.5 0.057
C 11.0 3.45–35.3 < 0.001
D 29.3 9.05–95.1 < 0.001
pT stage
pT1 1.00
pT2 1.62 0.21–12.8 0.648
pT3 6.33 0.88–45.5 0.067
pT4 9.89 1.31–75.0 0.067
pN stage
pN0 1.00
pN1 3.77 2.33–6.09 < 0.001
pN2 5.16 3.15–8.50 < 0.001
pM stage
pM0 1.00
pM1 5.31 3.55–7.93 < 0.001
Grade
I 1.00
II 1.38 0.60–3.17 0.445
III 1.07 0.36–3.18 0.906
IV 2.16 0.78–5.93 0.137
Side
Right 1.00
Left 1.45 0.92–2.28 0.107
Location
Colon 1.00
Rectum 1.16 0.79–1.69 0.453
Histologic type
Adeno 1.00
Mucinous 0.95 0.46–1.95 0.888
MMP-8 concentration
Low 1.00
High 1.72 1.17–2.52 0.005
MMP-9 concentration
Low 1.00
High 0.89 0.61–1.31 0.564
Table 4 Univariable Cox regression analysis of disease-specific
survival for colorectal cancer patients (Continued)
Hazard ratio 95% CI P-value
TIMP-1 concentration
Low 1.00
High 1.80 1.23–2.64 0.002
MMP-8/TIMP-1 ratio
Low 1.00
High 1.48 1.01–2.16 0.045
MMP-9/TIMP-1 ratio
Low 1.00
High 0.65 0.45–0.96 0.027
CRP (mg/l)
< =30 1.00
> 30 1.75 1.09–2.82 0.021
Abbreviations: MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of
metalloproteinases-1, CI confidence interval
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left-sided disease. These acknowledged differences in
genetic background explain why MMP expression influ-
ences prognosis in different ways. Instead of the
two-sided colon model – where right and left are di-
vided at the splenic flexure – a shift towards a multi-
segmental model displaying a continual shift in protein
expression may eventually better serve as a model [32].
CRP is a marker of systemic inflammation, with a con-
vincing prognostic influence in colorectal cancer [22,
33]. As on one hand, TIMP-1 has a growth factor-like
role directly affecting cancer cell growth, invasion, and
migration independent of TIMP:s inhibition of MMPs
[9, 10], and on the other hand, both MMPs and TIMP-1
play an important role in inflammatory processes, we
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explored whether MMPs and CRP correlate. We found a
weak positive correlation between MMP-8 and CRP
levels, as well as between TIMP-1 and CRP. In patients
with low CRP, high MMP-8 and TIMP-1 were prognos-
tic factors independent of CRP, whereas among patients
with high CRP reflecting a systemic inflammation re-
sponse, MMPs or TIMP-1 failed to select those patients
with a worse prognosis. In acute coronary syndrome,
MMP and CRP are correlated, and CRP seems to induce
local MMP-9 secretion [25]. In chronic urticaria, on the
other hand, high levels of MMP-9 and CRP are related
to disease severity [23]. Oral cancer patients with high
MMP-9 and CRP levels have had worse prognosis [34].
Few studies have reported on the relation between
MMP and CRP in CRC. During adenoma-carcinoma de-
velopment, a progressive increase in interleukin-8 (IL-8),
CRP, and MMP-9 occurs. Among 26 stage III colorectal
cancer patients, levels of MMP-9 and IL-8 were signifi-
cantly elevated and correlated with each other [35].
Likewise, MMP-8 correlates with high leukocyte and neu-
trophil count, whereas TIMP-1 correlates only weakly
with neutrophil count [14]. Among 525 colon cancer
cases, patients with high CRP had poor prognosis, a result
that was sustained within all disease stages when analyzed
separately [22]. Kostner et al. [33] demonstrated that even
among CRC patients with metastatic disease, high CRP
serves as a prognostic marker. MMP-8 is produced mainly
by neutrophils and reflects a response in the acute phase
of inflammation [5, 36]. Conversely, MMP-9 is produced
by several different cell types, so its serum levels are more
easily affected and any correlation with stage or prognosis
may thus be diluted [4].
We found that, compared with levels in healthy controls,
only TIMP-1 levels were marginally elevated among the
cancer patients. In contrast, in a study on 180 patients, of
whom 75 had colorectal cancer, MMP-9 and TIMP-1 levels
were higher in colorectal cancer patients than in healthy
controls or in colorectal adenoma patients [37]. In that
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study, MMP-9 and TIMP-1 also correlated with tumor
stage, but no data were presented on survival nor, in con-
trast with our results, did patients with colon cancer have
higher levels of MMP-9 than did rectal cancer patients.
Our primary aim was to study the prognostic role of
MMP-8, − 9, and TIMP-1, and thus, benign control pa-
tients could be few.
We investigated optimal cut-offs by the aid of
receiver-operating curves (ROC) and found them to be
close to median values. Therefore, we chose to dichotomize
our variables according to median values. Unfortunately, it
was impossible to study the correlation between serum and
tissue expression of MMP-8 and -9, because the previous
tissue results were from an earlier series studied at our in-
stitution [38]. In that series, we found that MMP-9 served
as a prognostic marker among Dukes B patients. However,
protein serum and tissue expression does not necessarily
correlate; local expression in tissue may reflect intact cells
and glands, and hence only small amounts of the protein
are released into the circulation.
Conclusions
Serum MMP-8 and TIMP-1 may serve as prognostic
factors in colorectal cancer. Among patients showing no
systemic inflammatory response, high MMP-8 and
TIMP-1 may associate with poor prognosis.
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